AstraZeneca at World ADC London 2027
Mar 8–11, 2027 London, UK ~700 attendees Website
AstraZeneca takes part in 3 sessions at World ADC London 2027 in London. Its program centers on making ADCs at scale, from setting impurity limits for drug-linker intermediates to aseptic manufacturing and a lysine conjugation platform built to keep pace with clinical demand.
| Organization | World ADC London 2027 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo. | Talk Talk Aseptic Manufacturing of Antibody-Drug Conjugates – From Process Development to Validation Manufacturing & supply chain Talk Wed Mar 10 3:30pm A Scalable Lysine Bioconjugation Platform: Reducing Development Burden as Clinical Demand Scales Process & analytical developmentManufacturing & supply chain Also |
Instantly find 20 buyers from AstraZeneca
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by World ADC or its organizers. Submit a correction